Posts tagged “Biotech & Life Science”
New plans for the Alexandria Center for Science, Technology and Agriculture have been released, and they include a world-class life science incubator and an in-house venture fund.
Neuro+, based in Durham, recently launched their technology, designed to help children--and adults--develop attention skills. The technology was designed with children diagnosed with ADHD in mind, yet is applicable and accessible to anyone that seeks to improve their attention skills.
The state-run program provides matching grants of up to $50,000 to North Carolina businesses that have received either federal Small Business Innovation Research (SBIR) or Small Business Technology Transfer (STTR) grant awards.
GSK has struck a development agreement with Idera Pharmaceuticals, Inc., which develops drugs for patients with renal disease. The deal comes with an up-front payment of $2.5 million to Idera, and is worth as much as $100 million.
Drug giant Pfizer and Allergan are merging in a deal valued at $160 billion, according to The Wall Street Journal. Pfizer has a number of operations across North Carolina. The deal would create the world's largest pharmaceutical company in sales.
AAIPharma Services Corp./Cambridge Major Laboratories, a drug development and manufacturing company, today announce an investment of $15.8 million to expand its laboratories and global headquarters in Wilmington over the next three years, creating at least 37 new jobs by 2018.
IBM is partnering with the Boston Children's Hospital with the goal of creating a cognitive system that will help clinicians interpret a child's genome sequencing data, compare this with medical literature, and quickly identify anomalies that may be responsible for the unexplained symptoms.
Three Triangle area companies have raised money according to recent regulatory filings. They are two biotechnology companies and a Raleigh-based firm that makes a photo enhancement and sharing app. Two are debt financings and one is an equity raise.
The American Heart Association and Google Life Sciences, a spinout of their parent company, are investing $50 million in a new initiative to address the challenges in preventing and curing coronary heart disease.
A Duke Medicine research team has identified a new molecular pathway involved in heart attacks and death from heart disease. The team operates out of the Durham Innovation District.
Cardioxyl Pharmaceuticals and Bristol-Myers Squibb have signed an agreement under which Bristol-Myers Squibb will acquire Cardioxyl and its assets in potential $2 billion deal.
World-renowned surgeon and researcher Dr. Anthony Atala will share his new approaches to health care and the impact new technologies are having in the medical community in November during NCREN Community Day in Winston-Salem.
Silver Spring, MD and Research Triangle Park-based United Therapeutics Corp. reported earnings that soared over analyst estimates for the third quarter of $5.02 a share on revenues of $386.2 million, up 17.1 percent from the same period a year ago. Analysts had estimated earnings at $2.44 a share.
GlaxoSmithKline, one of the Research Triangle's largest employers, saw increased sales in the third quarter that beat analysts estimates in the thrid quarter despite declining profits. It reported sales of $9.4 billion in the quarter, up 11 percent over the same period last year, but profits declined to $2.6 billion, a 5 percent drop.
Durham-based diagnostics developer SenGenix Inc. has raised just over a million dollars of a $1.5 million debt offering, according to a regulatory filing. The company is developing point-of-care diagnostic tests based on Duke University Medical Center technology.